Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — Investor Presentation (August 2020)
23 slides from Aim Immunotech's investor presentation, Aug 31, 2020
Slide 1: AIM ImmunoTech: Ampligen and Alferon
AIM ImmunoTech Ampligen and Alferon “Immunology for a better future”
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the statements included in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the Private
Slide 3: AIM ImmunoTech Inc. Robust Pipeline for Ampligen
AIM ImmunotTech Inc. We are an immuno-pharma company focused on Robust Pipeline for Ampligen in Oncology, COVID-19 the research and development of therapeutics to and ME/CFS treat multiple types of viral diseases, cancers, and ; Fl ; Le PORCH | institution] Pre-ciinical | Phase i | phase 2 | Phase3
Slide 4: Ampligen and COVID-19
Ampligen and COVID-19 ..a potential Prophylaxis for first responders and other medical professionals to essentially armor themselves against the virus before treating new and potential patients ..a potential Early-onset Therapeutic for people who have been exposed to the coronavirus so that they can
Slide 5: AIM's COVID-19 Efforts
AIM’s COVID-19 Efforts AIM has a signed clinical trial agreement with Roswell Park Comprehensive Cancer Center supporting Phase 1/2 clinical trial of Ampligen combined with Interferon Alfa-2b clinicaltrials.gov/NCT04379518) to test the safety and effectiveness of the combination regimen to clear the
Slide 6: Ampligen in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ampligen in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) * ME/CFS was originally considered a psychiatric based illness. Current a medical opinion considers ME/CFS to be a physically based illness of unknow - etiology. e Peer-reviewed medical journal articles now support the propositi
Slide 7: Ampligen and COVID-Induced CFS: 'COVID Survivor Syndrome'
Ampligen and COVID-Induced CFS: ‘COVID Survivor Syndrome’ "It is anticipated that COVID-19 will trigger a large number of CFS cases, providing an opportunity for the medical community to learn more about the onset and pathogenesis of CFS. The investigational immune-modulating antiviral drug Ampligen
Slide 8: Ampligen and Cancer: Animal Experiments
Ampligen and Cancer: Animal Experiments Ampligen + Checkpoint Blockade Synergistically Increased Survival/Anti-tumor Response Synergistic/anti-tumor responses at three different university centers using 3 different animal models in 3 different solid tumors have led to new collaborations: e An AIM gr
Slide 9: Ongoing Clinical Trial Objective: Convert 'Cold' Tumors Into 'Hot'
Ongoing Clinical Trial Objective: Prove Ampligen Converts ‘Cold’ Tumors Into ‘Hot’ Tumors that will be Responsive to Checkpoint Inhibitors e — Increase Intratumoral Effector T (Teff) cells e Decrease Intratumoral Regulatory T (Treg) cells e Goal is to unleash the cellular immune response to attack a
Slide 10: Ampligen and Cancer: Immuno-Oncology Thought Leaders
Ampligen and Cancer: Immuno-Oncology Thought Leaders Pawel Kalinski, MD, PhD, Vice Chair for Translational Research at Roswell Park Comprehensive Cancer Center, Buffalo, NY. “Ampligen is a selective activator of the TLR3 pathway, which selectively increases the production of factors which attract cy
Slide 11: Immuno-Oncology Clinical Trials Initiated / Ongoing in the U.S.
Ampligen and Cancer: Immuno-Oncology Clinical Trials Initiated / Ongoing in the U.S. Advanced Recurrent Ovarian Cancer - This Phase 1/2 study of Ampligen as an intraperitoneal therapy in advanced recurrent ovarian cancer has completed 12 subjects in Phase 1; the Phase 1 portion established intraperi
Slide 12: Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S.
Ampligen and Cancer: Immuno-oncology Clinical Trials Initiated / Ongoing in the U.S. Stage 4 Colorectal Cancer Metastatic to the Liver - Phase 2a study of Ampligen as a component of chemokine modulatory regimen on colorectal cancer metastatic to liver; the majority of the 12 planned patients enrolle
Slide 13: Ampligen and Cancer: Major Grant Awards
Ampligen and Cancer: Major Grant Awards e National Cancer Institute awarded $14.5 million to Roswell Park to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers e U.S. Department of Defense-funded Clinical Trial in Brain-Me
Slide 14: Expanded Access Program with Ampligen in Late-stage Pancreatic Cancer
Expanded Access Program (EAP) with Ampligen as a Standalone Treatment in Late- stage Pancreatic Cancer Site: Erasmus University, The Netherlands, conducted by Professor Casper van Eijck Eligibility: Adults with metastatic or locally advanced pancreatic carcinoma following FOLFIRINOX and adults post-
Slide 15: Alferon N Injection (interferon alfa-n3)
Alferon N Injection (interferon alfa-n3) ° Approved in the U.S. for the treatment of refractory or recurrent external genital warts in patients ages 18 or older. Approved in Argentina for the treatment of patients refractory to or intolerant to recombinant interferon alpha. Global market is open, as
Slide 16: Alferon N Injection Development Pipeline
Alferon N Injection Development Pipeline Pre; Di: Indicati A d Genital HPV (condylomata acuminata) Refractory to Recombinant IFN Intolerant to Recombinant IFN MERS* Influenza A (H7N9) Virus * Orphan Drug Indication in EU he. S BS S Bs ns. S BS US and Argentina Argentina Argentina Salm ImmunoTech NYS
Slide 17: IP Protection and Growing Patent Estate
IP Protection and Growing Patent Estate * 48 patents worldwide with 11 additional pending patent applications underway ° FDA granted Ampligen “orphan drug status” for CFS, HIV/AIDS, renal cell carcinoma and malignant melanoma ° Grants protection against potential subsequent approval of other version
Slide 18: AIM's Executive Management Team
AIM’s Executive Management Team ° Thomas K. Equels, M.S., J.D. / Chief Executive Officer — Equels was named Chief Executive Officer in February 2016 and has served as President since August 2015. Equels’ successful legal career included extensive experience in the pharma sector. He has over the year
Slide 19: Investment Highlights
Investment Highlights ¥ Advancing clinical trials of Ampligen as a potential protective prophylaxis and an early-onset treatment for COVID-19 v Japan evaluating Ampligen as a potential COVID-19 vaccine adjuvant v Ampligen believed to be the world’s only approved therapeutic for ME/CFS (first approva
Slide 20: Key Statistics
Key Statistics * Ticker: AIM « Exchange: NYSE American » Share Price (8/27/20) $2.43 « Shares Outstanding (8/13/20) 39.7M « Market Cap (8/27/20)* $96.5 M * Cash, Cash Equivalents & Marketable Securities (06/30/20): $40.3 M * Market Cap calculated using shares outstanding from 8/13/20 and Share Price
Slide 21: Supplemental Data
Supplemental Data: Aci 'y Only TLR3 agonist to promote selective attraction of CTLs (Teff) with concomitant increase in Teff/Treg ratio in the TME Reference(s)* Theodoraki, et al. (2018) Ampligen induces desirable chemokines in the TME, while other TLR3 agonists, such as poly IC, by activating helic
Slide 22: Supplemental Data
Supplemental Data: Activity Reference(s)* Induces dendritic cell maturation: Enhances bioactivity of cancer immunotherapy Nicodemus, et al. (2010) Promotes optimal dendritic cell maturation and Th1-type responses of healthy donors and cancer Navabi, et al. (2009) patients in vivo Induces epitope spr
Slide 23: Supplemental Data
Supplemental Data: Activity References Ampligen increases exercise performance in ME/CFS in Phase Ill, placebo-controlled trial Strayer, et al. (2012) Review of Ampligen clinical activity in ME/CFS Mitchell (2016) Low NK cell activity in ME/CFS increased by Ampligen (in vitro) Strayer, et al. (2015)